Open Label, Fixed Sequences, One-way Cross-over Study to Determine the Effects of Multiple Doses BAY1817080 (150 mg) on the Pharmacokinetics of a 5 mg Dose Rosuvastatin in Healthy Participants
Latest Information Update: 24 Dec 2020
At a glance
- Drugs Eliapixant (Primary) ; Rosuvastatin
- Indications Cough; Diabetic neuropathies; Endometriosis; Overactive bladder
- Focus Pharmacokinetics
- Sponsors Bayer
Most Recent Events
- 20 Dec 2020 Status changed from active, no longer recruiting to completed.
- 20 Nov 2020 Planned End Date changed from 29 Oct 2020 to 7 Dec 2020.
- 24 Aug 2020 Status changed from recruiting to active, no longer recruiting.